Tags: Drug.

Sitaxentan sodium (TBC-11251) is a medication for the treatment of pulmonary arterial hypertension (PAH). It was marketed as Thelin by Encysive Pharmaceuticals until Pfizer purchased Encysive in February 2008. In 2010 Pfizer voluntarily removed sitaxentan from the market due to concerns about liver toxicity.

Sitaxsentan.svg
ATC prefix
C02
ATC suffix
KX03
Bioavailability
70.0
CAS number
184036-34-8
CAS supplemental
210421-64-0 (sodium salt)
DrugBank
DB06268
FDA UNII code
J9QH779MEM
IUPAC name
N-(4-chloro-3-methyl-12-oxazol-5-yl)-2-[2-(6-methyl-2H-13-benzodioxol-5-yl)acetyl]thiophene-3-sulfonamide
PubChem
216235

Loading...

This page contains content from the copyrighted Wikipedia article "Sitaxentan"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.